Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes

[1] Fearon K(2011)Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 489-495

[2] Strasser F(2015)Cancer cachexia, recent advances, and future directions Cancer J 21 117-122

[3] Anker SD(2018)Cancer cachexia: diagnosis, assessment, and treatment Crit Rev Oncol Hematol 127 91-104

[4] Bosaeus I(2012)The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients Crit Rev Oncog 17 293-304

[5] Bruera E(2013)Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients Support Care Cancer 21 1569-1577

[6] Fainsinger RL(2013)Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results Clin Nutr 32 65-72

[7] Jatoi A(2014)Validation of the consensus-definition for cancer cachexia and evaluation of a classification model – a study based on data from an international multicentre project (EPCRC-CSA) Ann Oncol 25 1635-1642

[8] Loprinzi C(2015)Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer Support Care Cancer 23 1699-1708

[9] MacDonald N(2009)Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment Clin Cancer Res 15 2920-2926

[10] Mantovani G(2010)Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma Ann Oncol 21 1594-1598

[1] Fearon K(2011)Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 489-495

[2] Strasser F(2015)Cancer cachexia, recent advances, and future directions Cancer J 21 117-122

[3] Anker SD(2018)Cancer cachexia: diagnosis, assessment, and treatment Crit Rev Oncol Hematol 127 91-104

[4] Bosaeus I(2012)The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients Crit Rev Oncog 17 293-304

[5] Bruera E(2013)Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients Support Care Cancer 21 1569-1577

[6] Fainsinger RL(2013)Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results Clin Nutr 32 65-72

[7] Jatoi A(2014)Validation of the consensus-definition for cancer cachexia and evaluation of a classification model – a study based on data from an international multicentre project (EPCRC-CSA) Ann Oncol 25 1635-1642

[8] Loprinzi C(2015)Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer Support Care Cancer 23 1699-1708

[9] MacDonald N(2009)Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment Clin Cancer Res 15 2920-2926

[10] Mantovani G(2010)Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma Ann Oncol 21 1594-1598